Navigation Links
Puma Biotechnology Announces Completion of Private Placement
Date:11/23/2011

LOS ANGELES, Nov. 23, 2011 /PRNewswire/ -- Puma Biotechnology, Inc., a development stage biopharmaceutical company, today announced that on November 18, 2011, the Company completed the second tranche of its $60 million private financing. In the first tranche, announced on October 5, 2011, Puma sold approximately 14.7 million shares of its common stock to institutional investors at a purchase price of $3.75 per share, resulting in gross proceeds of $55 million.  In this second tranche, the Company sold approximately 1.3 million shares of its common stock to accredited investors at the same purchase price of $3.75 per share for gross proceeds of $5 million.  Proceeds from the financing will be used primarily to fund the continued clinical development of PB-272 (oral neratinib).

Leerink Swann LLC acted as lead placement agent and National Securities Corporation acted as co-placement agent for the second tranche of Puma's private financing. 

The securities sold in Puma's private financing have not been registered under the Securities Act of 1933, as amended, or state securities laws and may not be offered or sold in the United States absent registration with the Securities and Exchange Commission or an applicable exemption from the registration requirements.  This press release shall not constitute an offer to sell or the solicitation of an offer to buy these securities, nor shall there be any sale of these securities in any jurisdiction in which such offer, solicitation or sale would be unlawful prior to the registration or qualification under the securities laws of any such jurisdiction.

About Puma Biotechnology

Puma Biotechnology, Inc., is a development stage biopharmaceutical company that acquires and develops innovative products for the treatment of various forms of cancer.  The Company focuses on in-licensing drug candidates that are undergoing or have already completed initial clinical testing
'/>"/>

SOURCE Puma Biotechnology, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3

Related biology technology :

1. InNexus Biotechnology Announces Launch of Large Scale Primate Study of DXL625
2. Yongye Biotechnology International Retains CCG Investor Relations
3. Yongye Biotechnology International Announces Conference Call to Discuss Second Quarter 2008 Results
4. Yongye Biotechnology International Announces Second Quarter Results
5. BeaconEquity.com Issues Trade Alerts on Biotechnology Stocks: ELN, PFE, AMGN, DNA, BIIB, GILD
6. Lixte Biotechnology Holdings Announces Filing of a New Patent Application for Cancer Therapy Based on Targeting a Biomarker by Novel Investigational Agents
7. DuPont Obtains Biotechnology Endorsement for Pioneer(R) Brand Products
8. USDA Approves Syngenta and John Deere for Broadened Biotechnology Endorsement for Corn Crop Insurance
9. Crystal Research Associates, LLC Issues Executive Informational Overview(R) (EIO(R)) on Generex Biotechnology Corporation
10. InNexus Biotechnology CEO to Present at The Wall Street Analyst Forum in NYC
11. InNexus Biotechnology Strengthens Patent Team With New Leadership
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:8/21/2014)... August 21, 2014 2014 ... Industry” is a professional and in-depth research ... report provides basic Seaweed Fertilizer information, including ... chain structure as well as industry overview. ... including domestic market as well as global ...
(Date:8/21/2014)... New Rochelle, N.Y. (PRWEB) August 21, 2014 ... it is the first private college in the Mid-Hudson ... The College will now begin accepting applications from qualified ... , “We are very pleased to have been ... to support Governor Cuomo’s transformative initiative to stimulate economic ...
(Date:8/21/2014)... , Aug. 21, 2014  China Cord Blood Corporation (NYSE: ... plan to release financial results for the first quarter ... after market close in the US.  ... a.m. ET on Friday, August 29, 2014 to discuss ... the Company,s recent developments, followed by a question and ...
(Date:8/21/2014)... St. Louis, MO (PRWEB) August 21, 2014 ... premier, full service biopharmaceutical contract development and manufacturing ... selected by Progenics Pharmaceuticals, Inc., an oncology company ... targeting and treating cancer, to manufacture the anti-prostate ... Progenics’ PSMA ADC product candidate. Under the ...
Breaking Biology Technology:Internationals Seaweed Fertilizer Industry 2014 Development Trend Analysis in New Research Study at DeepResearchReports.com 2Internationals Seaweed Fertilizer Industry 2014 Development Trend Analysis in New Research Study at DeepResearchReports.com 3The College of New Rochelle Becomes First Private College in Mid-Hudson Region to Earn START-UP NY Designation 2The College of New Rochelle Becomes First Private College in Mid-Hudson Region to Earn START-UP NY Designation 3China Cord Blood Corporation to Report First Quarter of Fiscal 2015 Financial Results 2Gallus Enters Agreement with Progenics Pharmaceuticals, Inc. for Manufacture of Anti-PSMA Monoclonal Antibody 2Gallus Enters Agreement with Progenics Pharmaceuticals, Inc. for Manufacture of Anti-PSMA Monoclonal Antibody 3
... strategies to create vaccines for avian flu through ... genetically-engineered virus-like particles (VLPs), ROCKVILLE, Md., Nov. 13 ... its strategy for treating avian flu,through genetically-engineered virus-like particles ... Clinic 6th Annual Medical Innovation,Summit., Novavax, Inc. believes ...
... Genaera,Corporation (Nasdaq: GENR ) will present at ... Center in Mannheim, Germany. Dr. Henry,Wolfe, Executive Vice ... overview on Tuesday, November 18, 2008 at 11:00 ... is developing trodusquemine (MSI-1436) for type 2,diabetes and ...
... Covanta Holding,Corporation (NYSE: CVA ), a world ... renewable energy facilities, today,announced that it has amended ... co-owners Ridgewood Maine, L.L.C. and Indeck Energy,Services, Inc., ... agreed to acquire these,two facilities for approximately $52 ...
Cached Biology Technology:Cleveland Clinic Recognizes New Strategies for Creating Vaccines for Avian Flu as a Top Ten Medical Innovation for 2009 2Cleveland Clinic Recognizes New Strategies for Creating Vaccines for Avian Flu as a Top Ten Medical Innovation for 2009 3Cleveland Clinic Recognizes New Strategies for Creating Vaccines for Avian Flu as a Top Ten Medical Innovation for 2009 4Genaera to Present at BIO-Europe 2008 2Covanta Announces Amended Terms for its Acquisition of Two Biomass Energy Facilities in Maine 2Covanta Announces Amended Terms for its Acquisition of Two Biomass Energy Facilities in Maine 3Covanta Announces Amended Terms for its Acquisition of Two Biomass Energy Facilities in Maine 4
(Date:8/21/2014)... 2014 /PRNewswire-iReach/ -- LiveScan Service Provider  Binary ... a partnership with Gabriel Health Institute, one of ... Certified Nursing Assistant preparatory schools. The agreement ... member of Binary,s LiveScan service provider,s owner/operator team; ... its service capabilities by widening the service ...
(Date:8/21/2014)... of the water window? It consists of radiations in ... absorbed by the water in biological tissues. New theoretical ... radiations within the water window. These could be the ... image of the biological samples or to be used ... the physical mechanism needed to efficiently generate the harmonic ...
(Date:8/21/2014)... successfully replicated one of the crucial steps in photosynthesis, ... which could manufacture hydrogen as a fuel. , "Water ... exciting prospect to use them to create hydrogen, and ... from the ARC Centre of Excellence for Translational Photosynthesis ... offers potential as a zero-carbon replacement for petroleum products, ...
Breaking Biology News(10 mins):LiveScan Provider Binary Biometrics Announces Partnership with Preeminent CNA School, Gabriel Health Institute to Expand Services in Orlando Region 2LiveScan Provider Binary Biometrics Announces Partnership with Preeminent CNA School, Gabriel Health Institute to Expand Services in Orlando Region 3Water window imaging opportunity 2Water and sunlight the formula for sustainable fuel 2
... Cleveland Clinic and Riverain Medical today announced the ... to determine whether chest X-ray CAD (computer-aided detection) can ... program is designed to determine whether chest X-ray CAD ... an early stage when they are most treatable, leading ...
... arrived at the Red Planet. Almost four years later, ... its instruments send back a stream of images and ... its remarkable career by completing 5000 orbits of Mars. ... orbiter has revolutionised our knowledge of Mars, probing every ...
... human immunodeficiency virus (HIV-1) molecular machinery responsible for ... a study by investigators at the University of ... published November 23 in PLoS Computational Biology. ... of HIV-1 has so far foiled the best ...
Cached Biology News:Cleveland Clinic leading clinical program to improve early-stage lung cancer detection 2Mars Express -- 5000 orbits and counting 2Mars Express -- 5000 orbits and counting 3
... Use in any standard fixed-angle ... 16,000 g.,Spin- centrifuge tube filters ... within a centrifuge tube. They filter ... removal, HPLC sample preparation, removal of ...
... treated (or medium binding) polystyrene surface ... biomolecules through passive interactions,• Is suitable ... molecules, such as antibodies, that have ... with the surface,• Binding capacity of ...
... depth • Reusable, press-to-seal gasket and cover ... and disassembled for hybridizing and imaging thick ... with up to a 13 mm diameter. ... Minimize specimen handling, eliminate evaporation and leaking ...
Comp Dim: chamber diam. depth 20 2.8 mm chamber maximum volume 720 μL...
Biology Products: